( OTC-PINK:ENTBD,Bloomberg:E9B@GR,Bloomberg:ENTB@US,Bloomberg:ENTBD@US,RICS:ENTBD,ISIN:US29383T1025,OTC-BB:ENTBD )

News from Entest BioMedical, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Mar 09, 2017, 08:00 ET Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Announces Appointment of Dr. Thomas Donnelly to Serve as Senior Veterinary Advisor

Dr. Donnelly is an Internationally Recognized Animal Researcher, who the Company Believes Will Play an Important Role in the Development of...


Feb 15, 2017, 08:00 ET Entest BioMedical Inc.'s Zander Therapeutics Unit Announces Publication of Canine Cellular Immunotherapy Patent Application for Treating Cancer in Dogs

Entest BioMedical Inc.'s (OTCPINK: ENTB) wholly owned subsidiary, Zander Therapeutics Inc., announced today publication by the United States...


Feb 06, 2017, 08:30 ET Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Makes Key Additions to Management Team as the Company Prepares to Move Forward in the $63 Billion Veterinary / Pet Market Niche

Zander Prepares to Move Forward With Development of its Small Molecule Therapies for Treating Animals With Cancer and Autoimmune Disorders Which...


Feb 06, 2017, 08:30 ET Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Makes Key Additions to Management Team as the Company Prepares to Move Forward in the $63 Billion Veterinary / Pet Market Niche

Zander Prepares to Move Forward With Development of its Small Molecule Therapies for Treating Animals With Cancer and Autoimmune Disorders Which...


Jan 10, 2017, 08:00 ET Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Files Patent Application on its Proprietary NR2F6 Target for the Treatment of Exercise Induced Pulmonary Hypertension Frequently Found in Thoroughbred Horses

Entest BioMedical Inc. (OTCPINK: ENTB) announced today that its wholly owned subsidiary, Zander Therapeutics, Inc., has filed of a United States...


Dec 21, 2016, 11:25 ET Entest BioMedical, Inc. Chairman David Koos Discusses Zander Therapeutics Subsidiary and Future Plans for the Company Moving into 2017

Entest BioMedical, Inc. (OTCPINK: ENTB)(OTCBB: ENTB) Chairman & CEO David Koos discussed the Company's plans for 2017 including plans for...


Dec 21, 2016, 08:00 ET Entest BioMedical, Inc. Chairman David Koos Discusses Zander Therapeutics Subsidiary and Future Plans for the Company Moving into 2017

Entest BioMedical, Inc. (PINKS: ENTB) Chairman & CEO David Koos discussed the Company's plans for 2017 including plans for Zander...


Nov 18, 2009, 02:00 ET Entest BioMedical Files 3rd Patent Application for COPD Stem Cell Treatment

Entest BioMedical Inc. (OTC Bulletin Board: ENTB) announced today the filing of a third patent application relating to the area of chronic...


May 28, 2009, 10:30 ET New Stem Cell Web Site to Focus on Traumatic Brain Injury, Spinal Cord Injury and Diabetes

Entest BioMedical, Inc., a newly formed wholly-owned subsidiary of San Diego-based Bio-Matrix Scientific Group, Inc. (OTC Bulletin Board: BMSN)...